IKT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

-0.130

-80%

-0.142

-5%

Estimates Revision

The market is revising No Change the revenue expectations for Inhibikase Therapeutics, Inc. (IKT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.21%.

EPS Estimates for FY2025

Revise Upward

+0.38%

In Past 3 Month

Stock Price

Go Up

+5.21%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

H.C. Wainwright

Buy

initiated

2025-12-26

Reason

H.C. Wainwright

Price Target

2025-12-26

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Inhibikase Therapeutics with a Buy rating and $8 price target. The company recently announced plans to advance IKT-001 to a global pivotal Phase 3 clinical study in pulmonary arterial hypertension, the analyst tells investors in a research note. The firm says the drug's commercial prospects appear favorable, despite the presence of entrenched competition.

Cantor Fitzgerald

Olivia Brayer

Overweight

initiated

2025-12-11

Reason

Cantor Fitzgerald

Olivia Brayer

Price Target

2025-12-11

initiated

Overweight

Reason

Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Inhibikase Therapeutics with an Overweight rating and $4 price target. Inhibikase is now essentially defined by IKT-001, its oral imatinib prodrug being advanced directly into a pivotal Phase 3 for pulmonary arterial hypertension despite limited drug-specific data, the analyst tells investors in a research note. The program rests on a strong mechanistic rationale, which positions IKT-001 as a higher-risk but credible contender in a market increasingly focused on disease-modifying therapies, Cantor says.

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-28

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-28

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Hold

Downgrades

n/a

2025-02-12

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-02-12

Downgrades

Strong Buy

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT.O) is -3.98, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess Inhibikase Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.28

Current PE

-3.98

Overvalued PE

-0.31

Undervalued PE

-6.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

26.37

Current PS

0.00

Overvalued PS

62.18

Undervalued PS

-9.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IKT News & Events

Events Timeline

No data

News

9.5

2025-11-21Benzinga

Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading

5.0

2025-08-19Newsfilter

Inhibikase Therapeutics Enhances Leadership with Timothy Pigot's Appointment as Chief Commercial and Strategy Officer

9.5

2025-08-14Newsfilter

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

People Also Watch

Frequently Asked Questions

What is Inhibikase Therapeutics Inc (IKT) stock price today?

The current price of IKT is 1.715 USD — it has increased 2.69 % in the last trading day.

What is Inhibikase Therapeutics Inc (IKT)'s business?

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

What is the price predicton of IKT Stock?

What is Inhibikase Therapeutics Inc (IKT)'s revenue for the last quarter?

Inhibikase Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Inhibikase Therapeutics Inc (IKT)'s earnings per share (EPS) for the last quarter?

Inhibikase Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -80.00 % YoY.

What changes have occurred in the market's expectations for Inhibikase Therapeutics Inc (IKT)'s fundamentals?

How many employees does Inhibikase Therapeutics Inc (IKT). have?

Inhibikase Therapeutics Inc (IKT) has 15 emplpoyees as of January 11 2026.

What is Inhibikase Therapeutics Inc (IKT) market cap?

Today IKT has the market capitalization of 207.97M USD.